BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12), Zacks reports. The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $98.46 million. The company's quarterly revenue was up 4999.9% on a year-over-year basis. During the same period last year, the firm posted ($0.39) earnings per share.
BridgeBio Pharma Stock Up 1.4%
Shares of NASDAQ:BBIO traded up $0.63 during midday trading on Friday, reaching $46.58. 2,498,017 shares of the company were exchanged, compared to its average volume of 2,964,618. BridgeBio Pharma has a fifty-two week low of $21.72 and a fifty-two week high of $49.77. The stock has a fifty day simple moving average of $43.66 and a two-hundred day simple moving average of $37.47. The firm has a market cap of $8.90 billion, a PE ratio of -11.39 and a beta of 1.23.
Insider Buying and Selling at BridgeBio Pharma
In related news, Director Hannah Valantine sold 2,289 shares of the firm's stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $44.05, for a total transaction of $100,830.45. Following the sale, the director directly owned 398 shares in the company, valued at $17,531.90. This trade represents a 85.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Andrea Ellis sold 17,167 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $49.00, for a total transaction of $841,183.00. Following the sale, the director owned 18,589 shares in the company, valued at approximately $910,861. The trade was a 48.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,767,322 shares of company stock valued at $369,921,586 over the last quarter. 18.20% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On BridgeBio Pharma
An institutional investor recently bought a new position in BridgeBio Pharma stock. Jones Financial Companies Lllp purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,000 shares of the company's stock, valued at approximately $35,000. Institutional investors own 99.85% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently commented on BBIO shares. Wolfe Research assumed coverage on shares of BridgeBio Pharma in a research note on Tuesday, June 17th. They set an "outperform" rating and a $49.00 price target on the stock. Scotiabank upped their price objective on BridgeBio Pharma from $55.00 to $57.00 and gave the stock a "sector outperform" rating in a report on Wednesday. Wall Street Zen raised BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright upped their price objective on BridgeBio Pharma from $53.00 to $56.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Finally, Bank of America upped their price objective on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a "buy" rating in a report on Wednesday, June 25th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, BridgeBio Pharma currently has an average rating of "Moderate Buy" and an average target price of $61.35.
View Our Latest Research Report on BBIO
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Read More

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.